In Brief: Trinity Biotech
This article was originally published in The Gray Sheet
Executive Summary
Trinity Biotech: Acquires infectious disease and autoimmune diagnostic kit manufacturer Clark Laboratories for approximately $6.2 mil. in stock and cash. Trinity will issue 1.4 mil. shares of common stock in exchange for all of Clark's outstanding shares. Approximately two-thirds of the issued shares will be subject to a one-to-two-year "lock up" and can be bought back by Trinity at any time over the next two years at a premium ranging from 13% to 25% of the issued price, Trinity explains. Clark preferred stock will be redeemed by Trinity for approximately $1.5 mil. in cash. Jamestown, New York-based Clark had income of $237,000 on sales of $3.9 mil. for the 1996 fiscal year. With the acquisition, Trinity gains a 7% stake in CLI Oncology and an exclusive supply agreement with Wampole Laboratories to supply Clark's full range of diagnostic kits...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.